Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks

Core Viewpoint - Marinus Pharmaceuticals (MRNS) has experienced a downtrend with a 7.8% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2] - MRNS has an RSI reading of 9.98, indicating that heavy selling may be exhausting, which could lead to a price rebound [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts to raise earnings estimates for MRNS, resulting in a 16.4% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [6] - MRNS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7]